

## COURSE FACULTY, IAS–USA STAFF, AND BOARD OF DIRECTORS

### FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with ineligible companies (formerly commercial interests) within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” Below are the financial interests that faculty members of this course have had within the past 24 months as of the date listed. View the [Faculty Financial Disclosure Policy](#).

### HIV, COVID-19, AND SEXUALLY TRANSMITTED INFECTIONS: UPDATE AND IMPLICATIONS FOR PRACTICE – NOVEMBER 5, 2021

Course Presenters	
<p><b>Roger J. Bedimo, MD, MS</b> Chief, Infectious Diseases Section VA North Texas Health Care System Professor of Medicine UT Southwestern Medical Center Dallas, Texas</p>	<p>Dr Bedimo has received research funding from ViiV Healthcare and serves on the Scientific Advisory Board for Merck &amp; Co, Inc, ViiV Healthcare, and Gilead Sciences, Inc, and Theratechnologies. (Updated 11/2/21)</p>
<p><b>Constance A. Benson, MD</b> Professor of Medicine and Global Public Health Divisions of Infectious Diseases and Global Public Health ID Training Program Director Director, Antiviral Research Center PI/Director, HIV/AIDS Clinical Trials Unit University of California San Diego</p>	<p>Dr Benson has received research grants paid to her through her institution from Gilead Sciences, Inc. (Updated 11/03/21)</p>
<p><b>Connie L. Celum, MD, MPH</b> Professor of Global Health and Medicine Director, International Clinical Research Center Director, Center for AIDS Research University of Washington Seattle, Washington</p>	<p>Dr Celum has served as a scientific advisor to Merck &amp; Co, Inc, and Gilead Sciences, Inc. (Updated 10/26/21)</p>
<p><b>Meredith E. Clement, MD</b> Assistant Professor Infectious Diseases Louisiana State University Health Sciences Center New Orleans, Louisiana</p>	<p>Dr Clement has received research grants paid to her through her institution from Gilead Sciences, Inc, ViiV Healthcare, and Janssen. She has served on advisory boards for ViiV Healthcare and Roche. She receives royalties from UpToDate, Inc. (Updated 10/14/21)</p>
<p><b>Monica Gandhi, MD, MPH</b> Professor of Medicine Associate Division Chief of the Division of HIV, Infectious Diseases, and Global Medicine University of California San Francisco</p>	<p>Dr Gandhi has no relevant financial relationships with ineligible companies to disclose. (Updated 10/29/21)</p>
<p><b>Rajesh T. Gandhi, MD</b> Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts</p>	<p>Dr Gandhi has no financial affiliations with ineligible companies. (Updated 10/23/21)</p>
<p><b>Robert T. Schooley, MD</b> Professor of Medicine Division of Infectious Diseases Co-Director, Center for Innovative Phage Applications and Therapeutics Senior Director, International Initiatives University of California San Diego La Jolla, California</p>	<p>Dr Schooley has served as a consultant to CytoDyn and has received royalties from Antiva Biosciences and CytoDyn. He has served on the advisory board for Gilead Sciences, Inc., with payment remitted to his institution. He serves on the data and safety monitoring boards for Gilead Sciences, Inc., and VIR with payment remitted to his institution. (Updated 10/29/21)</p>

IAS–USA CME Planners and Reviewers	
<b>Monica Gandhi, MD, MPH</b>	Dr Gandhi has no relevant financial relationships with ineligible companies to disclose. (Updated 10/29/21)
<b>Rajesh T. Gandhi, MD</b>	Dr Gandhi has no financial affiliations with ineligible companies. (Updated 10/23/21)
<b>Robert T. Schooley, MD</b>	Dr Schooley has served as a consultant to CytoDyn and has received royalties from Antiva Biosciences and CytoDyn. He has served on the advisory board for Gilead Sciences, Inc., with payment remitted to his institution. He serves on the data and safety monitoring boards for Gilead Sciences, Inc., and VIR with payment remitted to his institution. (Updated 10/29/21)
<b>Donna M. Jacobsen</b> Executive Director/President IAS–USA	Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 11/03/21)

**IAS–USA Board of Directors**

\*The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see <https://iasusa.org/about/ias-usa-board-of-directors/> for information about board members and a link to up-to-date financial disclosure information.